Glucagon-Like Peptide-2 (GLP-2)
Also known as: GLP-2 analog, Teduglutide (pharmaceutical form)
A gut trophic hormone that enhances intestinal blood flow and nutrient absorption. Researched for short bowel syndrome and gastrointestinal healing.
On This Page
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Often transient and resolves within days to weeks of continued use. May be related to increased intestinal motility. Can be managed with consistent injection timing and ensuring adequate hydration.
Typically mild and self-resolving. May occur shortly after injection. Taking the injection at a consistent time and with food may help reduce incidence.
Erythema, swelling, or mild discomfort at injection site. Minimize by rotating injection sites, allowing solution to reach room temperature, and using proper injection technique. Usually resolves within hours.
Reported in some clinical trial participants. Typically mild and transient. Ensure adequate hydration and monitor frequency.
May occur due to improved intestinal function and nutrient absorption. Not necessarily adverse in short bowel syndrome patients who require increased caloric intake.
Reported rarely in clinical trials. Monitor for signs of peripheral edema, particularly in lower extremities. Ensure adequate electrolyte balance.
Rarely reported in clinical studies. Monitor mood and anxiety levels, particularly in individuals with pre-existing anxiety disorders.
GLP-2 may affect gallbladder contractility. Individuals with pre-existing gallbladder disease should use with caution and monitor for abdominal pain, nausea, or changes in bowel habits. Seek medical evaluation if symptoms develop.
Extremely rare but serious. Seek immediate medical attention if experiencing severe abdominal pain, elevated amylase/lipase levels, or other signs of pancreatitis. Discontinue use and consult healthcare provider.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 0.05-0.1 mg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 3790 |
| Half-life | 7 minutes (native GLP-2); 2-3 hours (teduglutide analog) |
| Sequence | Members only |
GLP-2 is a 33-amino acid peptide hormone secreted by intestinal L-cells that acts on GLP-2 receptors located on subepithelial myofibroblasts and enteric neurons. It enhances intestinal blood flow, increases mucosal thickness, and promotes nutrient absorption by stimulating intestinal epithelial cell proliferation and reducing apoptosis. GLP-2 also strengthens the intestinal barrier function and has been studied as a therapeutic for conditions involving compromised gut integrity, such as short bowel syndrome.
Track your Glucagon-Like Peptide-2 (GLP-2) research
Free account. No credit card required.
Recent Research
The Role of Vasoactive Intestinal Peptide in Glucagon-like Peptide-2-Mediated Intestinal Lipid Handling.
Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience.
[Gly(2)]-GLP-2(1-5): An ultra-short GLP-2 peptide for intestinal mucosal protection in inflammatory bowel disease.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Research Citations
5 sources
Jeppesen PB et al. (2005). Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 54(9):1224-1231. PMID: 15897551
Drucker DJ et al. (2006). Glucagon-like peptide-2 as a nutrient sensor. Physiology (Bethesda). 21:430-437. PMID: 17119151
Sigalet DL et al. (2007). A pilot study of growth hormone and glutamine-enriched nutrition in short bowel syndrome. Journal of Parenteral and Enteral Nutrition. 31(2):112-121. PMID: 17308251
Cummings DE et al. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 50(8):1714-1719. PMID: 11473029
PubMed PMID: 15897551 - Landmark study demonstrating teduglutide's ability to improve intestinal absorption and reduce parenteral nutrition dependence in short bowel syndrome patients
Related: Healing & Recovery
Browse the Research Library
133 peptide profiles and 54 blend profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesStay updated on Glucagon-Like Peptide-2 (GLP-2) research
Weekly digest of new peptide research, stack guides, and platform updates.
Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Glucagon-Like Peptide-2 (GLP-2) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.